{
    "nctId": "NCT02092467",
    "officialTitle": "PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS",
    "inclusionCriteria": "* Moderate to severe rheumatoid arthritis\n* Taking methotrexate without adequate control of symptoms\n* Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extra-articular RA disease)\n* Must have minimum age of 50 Years",
    "exclusionCriteria": "* Current or recent infection\n* Clinically significant laboratory abnormalities\n* Pregnancy"
}